Navigation Menu is only visible when JavaScript is enabled


  Rules and Guidelines
  Topic Categories
  Submission Instructions
  First Author Name Changes
  Acceptance and Programming
  Licensing Agreement
  How to Cite Abstracts
  Abstract FAQ's





ASHG Abstract Submission Rules and Guidelines



All authors will be asked to confirm the following statements when submitting an abstract: (1) I have read, understand and agree to the rules and guidelines; (2) I am submitting this abstract with the intent of attending the 2013 Annual Meeting and presenting; and (3) I confirm that each co-author has been informed of this abstract submission and has agreed to all information as it was submitted.


  1. Abstracts must be submitted with the intention that they will be presented if selected. First authors are expected to attend the meeting and make the presentation.  Authors should not submit abstracts if they do not plan to attend the meeting. Authors who cannot present as scheduled must notify the ASHG office in advance; authors who fail to do this may not be invited to present at future meetings. Substitution of the presenting/first author in platform/plenary presentations requires prior written approval from the Program Chair. Substitution is not allowed without prior written approval.


  2. An individual may be first author (i.e., presenting author) of only one abstract. If an abstract includes co-authors, the presenting author’s name should be the first name to appear in the author listing. 


  3. There is no limit to the number of times an individual may appear as co-author on abstracts. The first author must inform and have agreement from all co-authors of the abstract submission. The first author will be required to confirm this information during the abstract submission process.


  4. With regard to research using human subjects, ASHG endorses the protections embodied in the Basic Principles of the Declaration of Helsinki and their expansion in the regulations governing research supported by the U.S. Government (45 CFR Part 46; 56 FR 28003). ASHG does not endorse and will not publish the results of research that was not conducted in accordance with these Principles. Investigations involving animals reported in abstracts must have been conducted in conformance with approved principles of the care and use of animals in research.


  5. With regard to research where a gene is identified, the first/presenting author must present the gene symbol and/or name or the identified marker at the meeting. Authors who do not conform to this policy at the meeting will be subject to sanctions as determined by the Program Committee.


  6. A complete abstract should include a statement of purpose, methods used, and a summary of results in sufficient detail to support the conclusion.  Statements such as "results will be described" should be avoided.


  7. Abstract Programming: When submitting your abstract, please check the appropriate box indicating whether you wish your abstract to be considered for a platform (oral) or poster presentation. If there is any uncertainty about the first author’s ability to attend the meeting, a poster presentation should be selected. All abstracts submitted will be programmed at the discretion of the 2013 Program Committee.


  8. Prior Publication: Results or studies that have been published or that will be accepted for publication elsewhere prior to the submission deadline of June 4, 2013, as well as studies that will be published prior to October 2013, will be scored accordingly. This includes abstracts that have been accepted for presentation at another conference. Abstracts with new data will still be considered by the Program Committee.


  9. Review of Abstracts.  All abstracts are reviewed by at least one 2013 Program Committee member and two ad hoc reviewers.  The reviewing process is strictly confidential. The Program Committee reviews all abstracts submitted for presentation and determines whether an abstract is suitable for platform or poster presentation. The Program Committee reserves the right to decline a presentation to any submitted abstracts that lack scientific content or merit, or merely announce the availability of a resource or service.


  10. Abstract Licensing Agreement: In consideration of acceptance of the abstract by The American Society of Human Genetics (ASHG), the submitting author grants ASHG a nonexclusive, perpetual, worldwide license to copy, reproduce and publish the abstract in ASHG's online or print publication of ASHG abstracts and/or other compilations or collective works to be assembled and owned by ASHG (together, "Collective Works") in any form or medium now existing or hereafter created throughout the world. The submitting author understands and agrees that ASHG shall own all rights, including copyright, in and to the Collective Works including the right to: 

    1. Distribute, reproduce, license, display, perform, lend, lease, or transfer rights to the Collective Works to third parties,

    2. Prepare derivative works of the Collective Works, and

    3. Register the Collective Works in ASHGs own name with the U.S. Copyright Office. 


    It is understood that the submitting author and/or third parties with copyrights shall retain copyright in and to the abstract contributed by the submitting author to a Collective Work. The submitting author affirms that he/she is the author and owner of the abstract and holds all copyrights in and to the abstract, or has secured any third party permissions necessary to grant ASHG the above rights. The submitting author is responsible for providing any related third party with a copy of this grant of rights.


  11. Publication of Abstracts: Abstracts selected for presentation and publication will be available at the ASHG 2013 Web site in late August 2013.  At this time, your abstract and all information will become a matter of public record and may be referenced by ASHG, media relations staff and others. Please review the abstract licensing agreement/copyright policy above.



Contact Meeting Management


The American Society of Human Genetics, Incorporated | 9650 Rockville Pike, Bethesda, Maryland 20814 1-866-HUM-GENE (301) 634-7300
Privacy Policy